Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users
Abstract Background Limited evidence has indicated that addition of a steroidal mineralocorticoid receptor antagonist (MRA) to the standard of care reduces proteinuria in patients with diabetic kidney disease (DKD); however, there are limited data regarding real-world MRA use in these patients. This...
Main Authors: | Michael Blankenburg, Csaba P. Kovesdy, Anne-Kathrin Fett, Raymond G. Griner, Alain Gay |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-020-01719-7 |
Similar Items
-
Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
by: Byung Chul Yu, et al.
Published: (2018-09-01) -
Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01) -
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01) -
Spironolactone to treat hypertension in end-stage renal disease : analysis of effectiveness and safety
by: Smith, Amber Lanae
Published: (2014) -
Spironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration
by: Kapil G. Kapoor, et al.
Published: (2017-05-01)